Telomir Pharmaceuticals, Inc | WebDisclosure

Basculer en Français

11297	Companies
251095	Keywords
180062	Articles
136943	Press releases

Headlines Articles Press releases Telomir Pharmaceuticals, Inc

Home
Companies
Telomir Pharmaceuticals, Inc

PRESS RELEASE

published on 06/05/2025 at 14:30, 1 year 5 months ago

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Telomir-1 treatment shows promising results in reversing aging hallmarks in a rare genetic disorder. Findings include restored gene control, extended telomere length, muscle and weight recovery, reduced oxidative stress, and 100% survival

Preclinical Data Genetic Disorder Telomir-1 Age-Reversal Telomere Length
BRIEF

published on 06/02/2025 at 14:35, 1 year 5 months ago

Telomir Pharmaceuticals to Advance Age-Reversal Research at BIO 2025

Rare Diseases IND Submission Telomir-1 Age-Reversal Preclinical Success
BRIEF

published on 06/02/2025 at 14:35, 1 year 5 months ago

Telomir Pharmaceuticals fera progresser la recherche sur l'inversion du vieillissement au BIO 2025

Maladies Rares Telomir-1 Inversion Du Vieillissement Soumission IND Succès Préclinique
PRESS RELEASE

published on 06/02/2025 at 14:30, 1 year 5 months ago

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Telomir Pharmaceuticals, Inc. to meet prospective partners at BIO International Convention 2025 to accelerate IND submission for Telomir-1, preparing for human dosing in 2026

BIO International Convention IND Submission Telomir-1 Telomir Pharmaceuticals Human Dosing
BRIEF

published on 05/29/2025 at 14:35, 1 year 5 months ago

Telomir-1 Shows Promise in Restoring Vision in AMD Animal Model

Telomir-1 Retina Regeneration AMD Model Zebrafish Study Vision Restoration
BRIEF

published on 05/29/2025 at 14:35, 1 year 5 months ago

Telomir-1 s'avère prometteur pour restaurer la vision dans un modèle animal de DMLA

Telomir-1 Régénération De La Rétine Modèle AMD Étude Sur Le Poisson Zèbre Restauration De La Vision
PRESS RELEASE

published on 05/29/2025 at 14:30, 1 year 5 months ago

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints
Telomir Pharmaceuticals reports positive preclinical results for oral drug Telomir-1 in age-related macular degeneration (AMD) model, showing vision restoration, retinal regeneration, and reduced oxidative stress

Preclinical Results Telomir-1 Telomir Pharmaceuticals Age-related Macular Degeneration Vision Restoration
BRIEF

published on 05/15/2025 at 14:05, 1 year 5 months ago

Telomir Pharmaceuticals Introduces Telomir-Ag2, Targeting Drug-Resistant Infections

Antimicrobial Resistance Healthcare Market Telomir Pharmaceuticals Silver(II) Stabilization Drug-resistant Pathogens
BRIEF

published on 05/15/2025 at 14:05, 1 year 5 months ago

Telomir Pharmaceuticals présente Telomir-Ag2, un médicament ciblant les infections résistantes aux médicaments

Résistance Aux Antimicrobiens Telomir Pharmaceuticals Stabilisation À L'argent (II) Agents Pathogènes Résistants Aux Médicaments Marché De La Santé
PRESS RELEASE

published on 05/15/2025 at 14:00, 1 year 5 months ago

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
Telomir Pharmaceuticals, Inc. announces Telomir-Ag2, a novel drug candidate addressing antimicrobial resistance with broad-spectrum activity, particularly against drug-resistant pathogens

Antimicrobial Resistance Drug Candidate Telomir Pharmaceuticals Inc. Telomir-Ag2 Silver(II) Complex

Accesswire

Published on 11/09/2026 at 15:00, 8 minutes ago

Shelfietech Launched New Retail Software Platform
Published on 11/09/2026 at 14:30, 38 minutes ago

Boron One Applies for New Exploration Licence
Published on 11/09/2026 at 14:15, 53 minutes ago

Jericho Energy Ventures to Participate in Cantor Convergence 4th Annual Crypto and AI Infrastructure Conference
Published on 11/09/2026 at 14:00, 1 hour 8 minutes ago

Tectonic Metals Adds Mine Development and Alaska Native Partnership Leaders Ahead of 2027 Mineral Resource Estimate and Preliminary Economic Assessment
Published on 11/09/2026 at 13:35, 1 hour 33 minutes ago

Gabriel Provides Corporate Update

View all ACCESSWIRE

EQS Group

Published on 11/09/2026 at 14:55, 12 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 11/09/2026 at 14:54, 13 minutes ago

Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/09/2026 at 14:54, 13 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 11/09/2026 at 14:53, 14 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 11/09/2026 at 14:52, 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Rotork plc

Les Echos

Published on 11/09/2026 at 14:31, 36 minutes ago

261109 BENETEAU Transactions sur actions propres
Published on 11/09/2026 at 10:32, 4 hours 36 minutes ago

Disclosure of shares outstanding and voting rights - 09.11.2026
Published on 11/09/2026 at 10:32, 4 hours 36 minutes ago

Déclaration nombre d'actions et droits de vote - 09.11.2026
Published on 11/09/2026 at 07:00, 8 hours 8 minutes ago

bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 8 hours 8 minutes ago

BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA

View all LES ECHOS COMFI WIRE